Loading
A phase 3 trial of Icotinib in non-small-cell lung cancer and small-cell lung cancer, run by Betta Pharmaceuticals Co., Ltd., now recruiting.
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations is a phase 3 interventional study registered as NCT06041776 by Betta Pharmaceuticals Co., Ltd., with 570 participants planned, started 2023-03-28 and due to reach its primary completion in 2028-04-30. Interventions recorded: Befotertinib + Icotinib placebo, Icotinib + Befotertinib placebo. Conditions listed: Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy. No results are recorded here; the registry entry is the source.
Shares Resectable stage I to III non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Betta Pharmaceuticals, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Betta Pharmaceuticals, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Betta Pharmaceuticals, Resectable stage I to III non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Resectable stage I to III non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Icotinib, Resectable stage I to III non-small-cell lung cancer, Small-molecule kinase inhibitors.